PMC:7228307 / 2184-2436 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"31","span":{"begin":188,"end":192},"obj":"Gene"}],"attributes":[{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"esponses. These responses are also harnessed—or avoided—by therapeutic monoclonal antibodies. The use and manipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T29","span":{"begin":163,"end":173},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T30","span":{"begin":188,"end":190},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"esponses. These responses are also harnessed—or avoided—by therapeutic monoclonal antibodies. The use and manipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T8","span":{"begin":193,"end":201},"obj":"Chemical"}],"attributes":[{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"esponses. These responses are also harnessed—or avoided—by therapeutic monoclonal antibodies. The use and manipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent "}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T12","span":{"begin":202,"end":211},"obj":"http://purl.obolibrary.org/obo/BFO_0000034"}],"text":"esponses. These responses are also harnessed—or avoided—by therapeutic monoclonal antibodies. The use and manipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent "}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"31","span":{"begin":188,"end":192},"obj":"Gene"}],"attributes":[{"id":"A31","pred":"pubann:denotes","subj":"31","obj":"Gene:2213"}],"text":"esponses. These responses are also harnessed—or avoided—by therapeutic monoclonal antibodies. The use and manipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent "}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T15","span":{"begin":10,"end":93},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"esponses. These responses are also harnessed—or avoided—by therapeutic monoclonal antibodies. The use and manipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent "}

{"project":"LitCovid-sentences","denotations":[{"id":"T15","span":{"begin":10,"end":93},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"esponses. These responses are also harnessed—or avoided—by therapeutic monoclonal antibodies. The use and manipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent "}